Education
About Us
Working with TipRanks
Follow Us
Genprex Inc (GNPX)
NASDAQ:GNPX
GNPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.20 - $3.97
Previous Close$0.82
Volume416.42K
Average Volume (3M)2.69M
Market Cap
$7.73M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.35
Shares Outstanding33,466,785
10 Day Avg. Volume1,135,905
30 Day Avg. Volume2,687,296
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Genprex News
GNPX FAQ
What was Genprex Inc’s price range in the past 12 months?
Genprex Inc lowest stock price was $0.20 and its highest was $3.97 in the past 12 months.
What is Genprex Inc’s market cap?
Genprex Inc’s market cap is $7.73M.
When is Genprex Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Genprex Inc’s earnings last quarter?
Currently, no data Available
Is Genprex Inc overvalued?
According to Wall Street analysts Genprex Inc’s price is currently Overvalued.
Does Genprex Inc pay dividends?
Genprex Inc does not currently pay dividends.
What is Genprex Inc’s EPS estimate?
Genprex Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genprex Inc have?
Genprex Inc has 33,466,785 shares outstanding.
What happened to Genprex Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Genprex Inc?
Currently, no hedge funds are holding shares in GNPX
Company Description
Genprex Inc
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex (GNPX) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Brainstorm Cell Therapeutics
―
GT Biopharma
―
Aptorum Group
―
Lyra Therapeutics
―
Conduit Pharmaceuticals
―
Ownership Overview
0.23% Insiders
0.25% Mutual Funds
0.27% Other Institutional Investors
99.21% Public Companies and Individual Investors
Options Prices
Currently, No data available
---